UBS Group’s Eyegate Pharmaceuticals, Inc. Warrants EYEGW Stock Holding History

UBS Group’s Portfolio EYEGW Stock Details EYEGW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,508	Closed	–	–	8792
2020 Q2	$0	Sell	3,508 -277	-7%	-$12	﹤0.01%	8644
2020 Q1	$0	Buy	3,785 +185	+5%	+$5	﹤0.01%	8724
2019 Q4	$0	Buy	3,600 +3,490	+3,173%	+$118	﹤0.01%	8632
2019 Q3	$0	Sell	110 -2,435	-96%	-$72	﹤0.01%	8459
2019 Q2	$0	Buy	2,545 +2,000	+367%	+$67	﹤0.01%	8363
2019 Q1	$0	Buy	+545	New	+$17	﹤0.01%	8434
2018 Q4	–	Sell	-4,300	Closed	–	–	8488
2018 Q3	$0	Buy	+4,300	New	+$277	﹤0.01%	8430

UBS Group's EYEGW Position: Q3 2020 in Review

UBS Group sold out of Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) in Q3 2020, closing a stake of 3,508 shares.

UBS Group first reported a position in EYEGW in Q3 2018 and held it in 7 quarters. The position peaked at $0 in Q2 2020. 0 funds tracked by Wall St. Rank hold EYEGW as of Q3 2020.

UBS Group reported no remaining Eyegate Pharmaceuticals, Inc. Warrants position as of Q3 2020 after selling out during the quarter.
UBS Group sold 3,508 Eyegate Pharmaceuticals, Inc. Warrants shares in Q3 2020.
UBS Group first reported a position in Eyegate Pharmaceuticals, Inc. Warrants in Q3 2018 and held it in 7 quarters.
UBS Group's Eyegate Pharmaceuticals, Inc. Warrants position peaked at $0 in Q2 2020.
0 funds tracked by Wall St. Rank held Eyegate Pharmaceuticals, Inc. Warrants as of Q3 2020.

Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.